Erasca Inc (ERAS) Stock Price, Quote & News

Company Profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERA...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 465 6511

Website: www.erasca.com

Address:

3115 Merryfield Row, Suite 300, San Diego, United States

ForTGTX Mar. 13 at 8:37 PM

$ERAS Massive profit- taking AH 😢😢

1 · Reply

erevnon Mar. 13 at 3:21 PM

Mizuho maintains Erasca $ERAS at Outperform and raises the price target from $16 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

erevnon Mar. 13 at 11:47 AM

HC Wainwright & Co. maintains Erasca $ERAS at Buy and raises the price target from $15 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Alt_Fuel Mar. 11 at 10:48 AM

$VSTM $ERAS Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau - March 10, 2026 “We are encouraged by the early clinical activity observed for ERAS-0015 across multiple tumor types and RAS mutations at a fraction of the dose seen for RMC-6236. [ RMC-6236 is produced by $RVMD ] We believe that the clinical data generated to date, including what we have observed from a substantial number of patients treated in China, underscore the potential differentiation and benefit of ERAS-0015 for patients with RAS-mutant cancers globally,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Exercising this option to expand our license agreement and secure worldwide rights reflects our strong conviction in ERAS-0015’s potential, and we look forward to collaborating with the Chinese investigators to continue developing ERAS-0015 for patients in China and globally.” https://investors.erasca.com/news-releases/news-release-details/erasca-exercises-option-secure-worldwide-rights-eras-0015-pan

0 · Reply

Nothere2023 Mar. 10 at 6:26 PM

$ERAS RSI needs to cool a bit ?

0 · Reply

Alt_Fuel Mar. 10 at 6:20 AM

$VSTM Specific details on exact conferences and presentation dates for updated GFH375 (VS-7375) data in 2026 have not yet been publicly announced by GenFleet Therapeutics or its partner Verastem Oncology... $ANL ... $ERAS ... $RVMD However, Verastem has outlined plans to report an interim safety and efficacy update from the ongoing U.S.-based Phase 1/2 trial (VS-7375-101) in the first half of 2026, with a more comprehensive update in the second half of 2026. These timelines could align with major oncology conferences, such as: AACR Annual Meeting: April 17-22, 2026 (San Diego, CA). ASCO Annual Meeting: May 29-June 2, 2026 (Chicago, IL). Other global oncology events later in 2026 where data might be presented include ESMO Congress ( September ?) or the World Conference on Lung Cancer ( September ?)... GenFleet - intends to share updates across indications like NSCLC, PDAC, and other KRAS G12D-mutant solid tumors at international events throughout 2026 - no specific dates confirmed...

0 · Reply

Nothere2023 Mar. 9 at 5:20 PM

$ERAS Not going down, should break $18 🚀🚀🚀👍💥💥💥💪

0 · Reply

OptionRunners Mar. 9 at 3:44 PM

Potential profit taking in the $ERAS July 17th $12.50 calls. 1,075 contracts for $6.40. See what the OI shows tomorrow.

0 · Reply

LabPsycho Mar. 9 at 2:13 PM

$CCCC I am seeing several similarities between $CCCC, $TNGX and $ERAS - All with ~$300,000,000 cash, phase 1 and 2, molecular glues; all coming up from ~$1.2 lows last April, TNGX and ERAS ~ 10X in less than a year. Maybe that is why LabPsycho's A.^2 I. has CCCC predicted price of $6.62? I think its high but there could be some surprise factors built into the calculations. For amusement purposes only.

1 · Reply

1SwingSensei Mar. 8 at 4:24 AM

$ERAS Has been a homerun for us every trade, but once the news hit that they were added to the S&P our profits have been 10× or higher. 💰🫡

0 · Reply

Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

Mar 10, 2026, 8:00 AM EDT - 5 days ago

Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

Mar 5, 2026, 7:01 AM EST - 10 days ago

Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

Feb 24, 2026, 8:00 AM EST - 19 days ago

Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001

Feb 5, 2026, 8:00 AM EST - 5 weeks ago

Erasca to Present at Upcoming Conferences in February

Jan 26, 2026, 7:52 AM EST - 6 weeks ago

Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday?

Jan 23, 2026, 4:01 PM EST - 7 weeks ago

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 21, 2026, 8:54 PM EST - 7 weeks ago

Erasca Announces Pricing of Upsized Public Offering of Common Stock

Jan 20, 2026, 4:01 PM EST - 7 weeks ago

Erasca Announces Proposed Public Offering of $150 Million of Common Stock

Jan 12, 2026, 8:00 AM EST - 2 months ago

Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones

Jan 8, 2026, 1:21 PM EST - 2 months ago

What's Going With Cancer Biotech Erasca Stock On Thursday?

Jan 6, 2026, 8:00 AM EST - 2 months ago

Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 25, 2025, 9:08 AM EST - 3 months ago

Erasca to Present at the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 4:01 PM EST - 4 months ago

Erasca Reports Third Quarter 2025 Business Updates and Financial Results

Nov 6, 2025, 8:00 AM EST - 4 months ago

Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015

Nov 4, 2025, 8:00 AM EST - 4 months ago

Erasca to Present at Upcoming Conferences in November

Sep 2, 2025, 8:00 AM EDT - 6 months ago

Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 12, 2025, 4:01 PM EDT - 7 months ago

Erasca Reports Second Quarter 2025 Business Updates and Financial Results

Jun 2, 2025, 8:00 AM EDT - 10 months ago

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

May 29, 2025, 8:00 AM EDT - 10 months ago

Erasca to Present at Upcoming Investor Conferences in June

May 13, 2025, 4:05 PM EDT - 10 months ago

Erasca Reports First Quarter 2025 Business Updates and Financial Results

May 13, 2025, 8:00 AM EDT - 10 months ago

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

May 7, 2025, 8:00 AM EDT - 11 months ago

Erasca to Present at the Bank of America Securities Health Care Conference

Apr 29, 2025, 4:05 PM EDT - 11 months ago

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

Apr 25, 2025, 11:33 AM EDT - 11 months ago

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Mar 25, 2025, 4:31 PM EDT - 1 year ago

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Jan 31, 2025, 8:00 AM EST - 1 year ago

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Jan 27, 2025, 12:09 AM EST - 1 year ago

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Nov 12, 2024, 4:01 PM EST - 1 year ago

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Nov 5, 2024, 8:00 AM EST - 1 year ago

Erasca to Present at Upcoming Investor Conferences

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

May 21, 2024, 4:05 PM EDT - 1 year ago

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

May 16, 2024, 8:02 PM EDT - 1 year ago

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

May 16, 2024, 8:00 PM EDT - 1 year ago

Erasca Announces Pricing of Underwritten Offering of Common Stock

May 8, 2024, 4:01 PM EDT - 2 years ago

Erasca Reports First Quarter 2024 Business Updates and Financial Results

May 7, 2024, 8:00 AM EDT - 2 years ago

Erasca to Present at the Bank of America Health Care Conference

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Mar 29, 2024, 11:11 AM EDT - 2 years ago

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

Mar 27, 2024, 8:30 PM EDT - 2 years ago

Erasca Announces $45 Million Oversubscribed Private Placement Financing

Mar 27, 2024, 4:01 PM EDT - 2 years ago

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Jan 3, 2024, 8:00 AM EST - 2 years ago

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 8:00 AM EST - 2 years ago

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Nov 28, 2023, 8:00 AM EST - 2 years ago

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Nov 9, 2023, 4:01 PM EST - 2 years ago

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

Nov 8, 2023, 8:00 AM EST - 2 years ago

Erasca to Present at Upcoming Investor Conferences in November

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 29, 2023, 8:00 AM EDT - 2 years ago

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

Aug 28, 2023, 6:05 AM EDT - 2 years ago

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

AMGN BLUE CAT CSCO CVX DOW IBM

Aug 14, 2023, 3:22 PM EDT - 2 years ago

August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February

CVX PUMP

ForTGTX Mar. 13 at 8:37 PM

$ERAS Massive profit- taking AH 😢😢

1 · Reply

erevnon Mar. 13 at 3:21 PM

Mizuho maintains Erasca $ERAS at Outperform and raises the price target from $16 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

erevnon Mar. 13 at 11:47 AM

HC Wainwright & Co. maintains Erasca $ERAS at Buy and raises the price target from $15 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Alt_Fuel Mar. 11 at 10:48 AM

0 · Reply

Nothere2023 Mar. 10 at 6:26 PM

$ERAS RSI needs to cool a bit ?

0 · Reply

Alt_Fuel Mar. 10 at 6:20 AM

0 · Reply

Nothere2023 Mar. 9 at 5:20 PM

$ERAS Not going down, should break $18 🚀🚀🚀👍💥💥💥💪

0 · Reply

OptionRunners Mar. 9 at 3:44 PM

Potential profit taking in the $ERAS July 17th $12.50 calls. 1,075 contracts for $6.40. See what the OI shows tomorrow.

0 · Reply

LabPsycho Mar. 9 at 2:13 PM

1 · Reply

1SwingSensei Mar. 8 at 4:24 AM

$ERAS Has been a homerun for us every trade, but once the news hit that they were added to the S&P our profits have been 10× or higher. 💰🫡

0 · Reply

WallStreetBuyDip Mar. 6 at 4:13 PM

watching $ERAS closely. will enter when H% shows low like in this example

0 · Reply

ZacksResearch Mar. 6 at 3:19 PM

$TNGX surges 36.3% on Thursday — what’s behind the rally? A new clinical trial collaboration with $ERAS is fueling the excitement. The partnership aims to tackle MTAP-deleted RAS-mutant cancers, a space with limited options, using a promising combo strategy. Discover the full story here 👉 https://www.zacks.com/stock/news/2880099/tngx-stock-hits-record-high-on-inking-collaboration-deal-with-eras?cid=sm-stocktwits-2-2880099-body-36351&ADID=SYND_STOCKTWITS_TWEET_2_2880099_BODY_36351

0 · Reply

Quantumup Mar. 6 at 2:27 PM

Clear Street⬆️ $ERAS's PT to $20 from $11 and reiterated at a Buy rating. $TNGX $IMRX $RVMD $BBOT Erasca announced a clinical trial and supply agreement (CTCSA) with Tango Therapeutics (TNGX, NC) to evaluate ERAS-0015 in combination with Tango's PRMT5 inhibitor, vopimetostat (TNG462). We view this as a capital-efficient initiative that increases ERAS-0015's combination flexibility and brings an MTAPdel RASm approach. We raise our PT to $20 (from $11) based on (1) higher PoS for ERAS-0015—55% in PDAC, 40% in NSCLC (up from 30% each), reflecting notable MTAP deficiency prevalence (35% for PDAC, 15% for NSCLC per Tango) and confidence in an additional combination strategy, and (2) a reduced discount rate to 12% (from 13%) on increased external validation.

0 · Reply

erevnon Mar. 6 at 11:33 AM

Clear Street maintains Erasca $ERAS at Buy and raises the price target from $11 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Alt_Fuel Mar. 5 at 7:21 PM

$VSTM Jefferies reiterates Verastem $VSTM stock rating on launch progress - 03/05/2026, 10:54 AM https://www.investing.com/news/analyst-ratings/jefferies-reiterates-verastem-stock-rating-on-launch-progress-93CH-4544702 Next 6 to 12 months will be interesting ... $ERAS $ANL $RVMD

0 · Reply

TICKERTUTOR Mar. 5 at 3:21 PM

sold $ERAS and bought $BOLD

0 · Reply

xUltraCash Mar. 5 at 2:53 PM

$ERAS gooooo

0 · Reply

Thestocktraderhubzee Mar. 5 at 12:26 PM

$ERAS Erasca And Tango Therapeutics Enter Clinical Collaboration To Evaluate ERAS-0015 With Vopimetostat In Phase 1/2 Trial For MTAP-Deleted Pancreatic Cancer And NSCLC

0 · Reply

xUltraCash Mar. 5 at 12:09 PM

$ERAS rise,…

0 · Reply

TheTradeXchange Mar. 5 at 12:01 PM

$ERAS - Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

0 · Reply

DaPod Mar. 5 at 1:32 AM

$ERAS Sadly I just started having interest in ERAS after their presentation at the J P Morgan conference and reading the transcript on Jan 14 I am now very interested in it. The stock had moved up from 4 area to 8 and then 10 so I thought I would wait. Then on Jan 20 they announced they were going to sell $150 million in an offering which they did on Jan 22 at $10 per share and they ended up selling $225 million of shares. With the interesting presentation at J P Morgan, and as the stock had moved quickly from 4 to 10 - then an offering - it seemed a stock moving this far so rapidly would drop back - wrong again as it has continued to climb. Their presentation was strong and they are in the same area as Revolution Medicines. Some early reports showed the ERAS treatment may be more effective on smaller dosage. Bottom line - RVMD is $100 with Market Cap $20 Billion Eras is 15 today with $4.5 Market Cap. Take a look at ERAS and post your thoughts thanks! Finally bought some!!

0 · Reply

outlawinvestor1 Mar. 4 at 10:58 PM

$ERAS my biggest roi next to $ABVX

1 · Reply

Market Cap	4.22B
Revenue (ttm)	0.00
Net Income (ttm)	-161.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,345,400
Avg Vol	6,480,566
Day's Range	N/A - N/A
Shares Out	309.59M
Stochastic %K	3%
Beta	1.16
Analysts	Strong Sell
Price Target	$14.70